BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld Asia
Home
» China's Generon receives U.S. FDA SPA for pivotal trial of G-CSF candidate
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
China's Generon receives U.S. FDA SPA for pivotal trial of G-CSF candidate
Oct. 18, 2017
By
David Ho
No Comments
HONG KONG – Generon Corp. (Shanghai) Ltd. has reached an agreement with the FDA under a special protocol assessment (SPA) regarding the second pivotal global phase III study design of its chemotherapy-induced neutropenia (CIN) treatment.
BioWorld Asia